SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Accuretic Tablets

Trade Name: Accuretic; Accuzide; Acuilix; Aquinaretic; Accumax; Accupro; Acupil H; Hemokvin Plus
Synonyms: Quinapril and Hydrochorothiazide Tablets
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antihypertensive

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

Label Elements

Signal Word: Warning
Hazard Statements: H361d - Suspected of damaging the unborn child

Precautionary Statements:
P201 - Obtain special instructions before use
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Quinapril hydrochloride	82586-55-8	Not Listed	Repr.2 (H361d)	10.5
Hydrochlorothiazide	58-93-5	200-403-3	Not Listed	6.1-12.1
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Magnesium carbonate	39409-82-0	Not Listed	Not Listed	*
Crospovidone	9003-39-8	Not Listed	Not Listed	*
Lactose hydrous	64044-51-5	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Quinapril hydrochloride

Pfizer OEL TWA-8 Hr: 100µg/m^3

Hydrochlorothiazide

Pfizer OEL TWA-8 Hr: 250µg/m^3

Magnesium stearate

Lithuania OEL - TWA 5 mg/m^3

Sweden OEL - TWAs 5 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablet	**Color:**	Pink
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Hydrochlorothiazide
No data available
Quinapril hydrochloride
Predicted 7 Log P 3.41
Povidone
No data available
Magnesium carbonate
No data available
Lactose hydrous
No data available
Crospovidone
No data available
Magnesium stearate
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:
- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- **Oxidizing Properties:** No data available
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers
- **Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: Antihypertensive drug: has blood pressure-lowering properties
Accidental ingestion may cause effects similar to those seen in clinical use. In humans, the use of drugs in this class (ACE inhibitors) can cause fetal and neonatal toxicity, including low blood pressure and kidney failure, when they are taken during pregnancy.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on kidneys, liver, gastrointestinal system, heart, and blood.
Known Clinical Effects: Effects reported during clinical use include dizziness, headache, lethargy, changes in blood pressure, nausea, and abdominal pain.

Acute Toxicity: (Species, Route, End Point, Dose)

Hydrochlorothiazide
Rat Oral LD 50 2750 mg/kg
Mouse Oral LD 50 2830mg/kg
Rat Intravenous LD 50 990mg/kg
Dog Intravenous LD 50 250mg/kg

Quinapril hydrochloride
Rat Oral LD50 3541 mg/kg
Mouse Oral LD50 1478mg/kg
Rat IV LD50 107mg/kg

Povidone
Rat Oral LD50 100 g/kg

11. TOXICOLOGICAL INFORMATION

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m^3
Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Quinapril hydrochloride
Skin Sensitization - GPMT Guinea Pig Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Hydrochlorothiazide
30 Day(s) Rat Oral 1 g/kg/day LOAEL Blood
13 Week(s) Mouse Oral 12,500 ppm LOAEL Bladder
9 Month(s) Dog Oral 50 mg/kg/day LOAEL Endocrine system
1 Year(s) Rat Oral 2000 ppm LOAEL Kidney
2 Year(s) Rat Oral 250 ppm LOAEL Kidney

Quinapril hydrochloride
13 Week(s) Rat Oral 50 mg/kg/day LOAEL Gastrointestinal System, Blood, Heart, Kidney
13 Week(s) Dog Oral 25 mg/kg/day NOAEL Kidney, Blood, Liver, Gastrointestinal system
52 Week(s) Rat Oral 10 mg/kg/day LOAEL Kidney
52 Week(s) Dog Oral 10 mg/kg/day NOAEL Blood, Gastrointestinal system, Heart, Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Hydrochlorothiazide
Reproductive & Fertility Rat Oral 1000 mg/kg LOAEL Maternal toxicity
Reproductive & Fertility Mouse Oral 3000 mg/kg/day NOEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOEL Not Teratogenic
Embryo / Fetal Development Mouse Oral 3000 mg/kg/day NOEL Not Teratogenic

Quinapril hydrochloride
Peri-/Postnatal Development Rat Oral 150 mg/kg/day NOAEL No effects at maximum dose
Reproductive & Fertility Rat Oral 100 mg/kg/day NOAEL No effects at maximum dose
Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic, No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Hydrochlorothiazide
Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Positive
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative
Dominant Lethal Assay Drosophila Negative
Mammalian Cell Mutagenicity Mouse Lymphoma Positive

Quinapril hydrochloride
Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative
In Vitro Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Negative

11. TOXICOLOGICAL INFORMATION

In Vivo Cytogenetics Rat Bone Marrow Negative
In Vivo Micronucleus Mouse Bone Marrow Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Hydrochlorothiazide
2 Year(s) Rat Oral 2000 ppm NOAEL Not carcinogenic
2 Year(s) Female Mouse Oral 5000 ppm NOAEL Not carcinogenic
2 Year(s) Male Mouse Oral 5000 ppm LOAEL Malignant tumors, Liver

Quinapril hydrochloride
104 Week(s) Rat Oral 100 mg/kg/day NOAEL Not carcinogenic
104 Week(s) Mouse Oral 75 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Hydrochlorothiazide
IARC: Group 2B (Possibly Carcinogenic to Humans)

Povidone
IARC: Group 3 (Not Classifiable)

Crospovidone
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Quinapril hydrochloride
Predicted 7 Log P 3.41

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Quinapril hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Hydrochlorothiazide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-403-3

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Magnesium carbonate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	Not Listed

Crospovidone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Lactose hydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Povidone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Data Sources:	Pfizer proprietary drug development information.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.
Revision date:	01-Aug-2018
	Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet